(Reuters) – The U.S. Food and Drug Administration issued a new warning on the use of the anticoagulant Lovenox in patients fitted with a spinal catheter because of the risk of spinal column bleeding and potential paralysis.
The FDA said on Wednesday that healthcare professionals should carefully consider timing when inserting or removing a spinal catheter in patients taking Lovenox, which is made by Sanofi SA, or its generic versions, which are sold under the name enoxaparin.
